louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04444596: Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19
Official title: Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: COVID-19
SARS-CoV 2
Lead sponsor: Medical University Innsbruck
Sponsor class: OTHER
First posted: 2020-06-23
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The aim of this possible study is to identify if SARS-CoV-2 can be found in the tear film and conjunctiva of a patient with COVID-19.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* A confirmed COVID-19 disease
* Signed and dated declaration of consent
* The patient fell ill in Tyrol

Exclusion Criteria:

* none

Primary outcomes:
measure: SARS-CoV2 positive conjunctival swabs
timeFrame: 1 year
Secondary outcomes:
measure: Conjunctival swab vs nasopharyngeal swab
timeFrame: 1 year
Other outcomes:
measure: Viability of SARS-COV 2
timeFrame: 1 year
Locations:
city: Innsbruck
country: Austria
facility: Medical University Innsbruck
state: Tirol
Study officials:
References:
Clinical trial NCT02989896: Perfusion Index in the Success of Peripheral Nerve Block
Official title: Evaluation of Perfusion Index in the Success of Peripheral Nerve Block in Advanced Age Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Perfusion Index
Peripheral Nerve Block Success
Keywords: Perfusion index
Peripheral nerve block success
older age
Lead sponsor: Erzincan University
Sponsor class: OTHER
First posted: 2016-12-12
Enrollment: 120
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Elective orthopedic lower extremity surgery patients

Brief summary: After a successful peripheral nerve block, blockade of sympathetic nerve fibers results in local vasodilatation, increased local blood flow, and increased skin temperature.Increased permeability index; Can be used as a reliable tool for evaluating block activity.


Eligibility criteria: Inclusion Criteria:

* Over 65 years old
* ASA I-III

Exclusion Criteria:

* Patients under 65 years old
* Patients contraindicated in regional anesthesia
* Patients with local anesthetic allergy
* Patients with injection site infection
* Patients who do not accept the procedure

Primary outcomes:
measure: patient's perfusion index
timeFrame: nine month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Curatolo M, Petersen-Felix S, Arendt-Nielsen L. Sensory assessment of regional analgesia in humans: a review of methods and applications. Anesthesiology. 2000 Dec;93(6):1517-30. doi: 10.1097/00000542-200012000-00025. No abstract available.
citation: Pearson AC, Gudipati CV, Labovitz AJ. Effects of aging on left ventricular structure and function. Am Heart J. 1991 Mar;121(3 Pt 1):871-5. doi: 10.1016/0002-8703(91)90201-r.
citation: Lima AP, Beelen P, Bakker J. Use of a peripheral perfusion index derived from the pulse oximetry signal as a noninvasive indicator of perfusion. Crit Care Med. 2002 Jun;30(6):1210-3. doi: 10.1097/00003246-200206000-00006.
citation: Kus A, Gurkan Y, Gormus SK, Solak M, Toker K. Usefulness of perfusion index to detect the effect of brachial plexus block. J Clin Monit Comput. 2013 Jun;27(3):325-8. doi: 10.1007/s10877-013-9439-4. Epub 2013 Feb 10.
citation: Galvin EM, Niehof S, Verbrugge SJ, Maissan I, Jahn A, Klein J, van Bommel J. Peripheral flow index is a reliable and early indicator of regional block success. Anesth Analg. 2006 Jul;103(1):239-43, table of contents. doi: 10.1213/01.ane.0000220947.02689.9f.
citation: Sebastiani A, Philippi L, Boehme S, Closhen D, Schmidtmann I, Scherhag A, Markstaller K, Engelhard K, Pestel G. Perfusion index and plethysmographic variability index in patients with interscalene nerve catheters. Can J Anaesth. 2012 Dec;59(12):1095-101. doi: 10.1007/s12630-012-9796-3. Epub 2012 Oct 2.
citation: Goldman JM, Petterson MT, Kopotic RJ, Barker SJ. Masimo signal extraction pulse oximetry. J Clin Monit Comput. 2000;16(7):475-83. doi: 10.1023/a:1011493521730.
Clinical trial NCT01544296: A Comparative Study of KHK6188
Official title: Phase II Study of KHK6188 (A Placebo-controlled, Double Blind, Crossover Study of KHK6188 in Postherpetic Neuralgia)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Postherpetic Neuralgia
Lead sponsor: Kyowa Kirin Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2012-03-05
Enrollment: 42
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This is a placebo-controlled, double blind, crossover study to evaluate the efficacy and safety of KHK6188 in postherpetic neuralgia when administered orally for 2 weeks.


Eligibility criteria: Inclusion Criteria:

* Patients with pain for ≥ 3 months and ≤ 1 year following onset of a herpes zoster rash
* Patients with a mean pain intensity score (11-point numerical rating scale) of ≥ 4
* Patients whose rash has been healed
* Patients who are able to fill their patient diary
* Patients who provided written voluntary informed consent to participate in the study

Exclusion Criteria:

* Patients who have other pain or disease which may impair the self assessment of pain
* Patients who have dementia, depression or schizophrenia which may affect the self assessment of pain
* History or presence of severe cardiovascular disease, hepatic dysfunction, renal failure, respiratory disease, blood disease or CNS disorder
* History or presence of a drug allergy
* Patients who have a history of a diagnosis of cancer or a treatment of cancer within 5 years prior to the study entry
* Patients received an investigational medication within 4 months (6 months for biologic medication such as antibody) prior to the informed consent
* Women of child bearing potential who do not agree to avoid pregnancy from the time of providing the consent until 3 months after the end of dosing, or men of reproductive potential who do not agree to avoid pregnancy from the time of the first dose until 3 months after the end of dosing
* Patients who are pregnant, lactating, or possibly pregnant
* Patients judged to be inappropriate to enter the study by a investigator or a subinvestigator

Primary outcomes:
measure: Change of pain intensity score
timeFrame: baseline and 2weeks
Secondary outcomes:
measure: Change of allodynia severity
timeFrame: baseline and 2 weeks
measure: Change of global impression
timeFrame: baseline and 2 weeks
Other outcomes:
Locations:
city: Arakawa-ku
country: Japan
facility: Japan
state: Tokyo
Study officials:
References:
Clinical trial NCT02835196: Optical Elastography of Systemic Sclerosis Skin
Official title: Optical Elastography of Systemic Sclerosis Skin
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Scleroderma
Lead sponsor: The University of Texas Health Science Center, Houston
Sponsor class: OTHER
Collaborators: name: University of Houston
First posted: 2016-07-15
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients seen in clinic.

Brief summary: The goal of this study is to develop a new way to assess skin thickness in patients with scleroderma (systemic sclerosis). The study will test how well a new imaging method called optical coherence elastography (OCE) compares to the current clinical method used to estimate skin thickness, the modified Rodnan Skin Score (mRSS).


Eligibility criteria: Inclusion Criteria for scleroderma patients:

* meet the 2013 American College of Rheumatology and the European League Against Rheumatism (ACR/EULAR) criteria for systemic sclerosis with limited or diffuse cutaneous involvement

Exclusion Criteria:

* have another skin disease other than systemic sclerosis

Primary outcomes:
measure: Skin optical elastography (OCE) scan score
timeFrame: Baseline
Secondary outcomes:
measure: Skin thickness as assessed by Modified Rodnan Skin Score (mRSS)
timeFrame: Baseline
measure: Fibrosis score as assessed by forearm skin punch biopsy
timeFrame: Baseline
measure: Disability as assessed by the Scleroderma Health Assessment Questionnaire
timeFrame: Baseline
Other outcomes:
Locations:
city: Houston
country: United States
facility: The University of Texas Health Science Center at Houston
state: Texas
Study officials:
affiliation: The University of Texas Health Science Center, Houston
name: Shervin Assassi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06636396: Feasibility of Measuring Skin Carotenoid Level in an Asthma Clinic
Official title: Feasibility of Measuring Skin Carotenoid Level in an Asthma Clinic
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Asthma
Lead sponsor: University of Kansas Medical Center
Sponsor class: OTHER
First posted: 2024-10-10
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All people with asthma who are at least 18 years of age.

Brief summary: The purpose of this study is to assess the use of a practical tool to objectively measure the fruit and vegetable intake in people with asthma.

Detailed description: After consenting to join the study, all participants enter a single cohort, cross-sectional study to assess pulmonary function, asthma control, carotenoid level, and diet intake.

Eligibility criteria: Inclusion Criteria:

* Pulmonary patients 18 years of age and older
* Confirmed diagnosis of asthma by a physician and confirmed by a pulmonary physician
* English speaking
* Access to the internet

Exclusion Criteria:

* Acute upper or lower respiratory infection
* Systemic corticosteroids
* Recent or current confirmed diagnosis of Covid-19

Primary outcomes:
measure: FEV1
timeFrame: measured at a single time point when recruited in the study (cross sectional). Study outcomes will be reported upon study completion, approximately 1 year from study onset.
measure: ACT
timeFrame: measured at a single time point when recruited in the study (cross sectional). Study outcomes will be reported upon study completion, approximately 1 year from study onset.
measure: Skin Carotenoid Level
timeFrame: measured at a single time point when recruited in the study (cross sectional). Study outcomes will be reported upon study completion, approximately 1 year from study onset.
measure: Diet Intake
timeFrame: measured at a single time point when recruited in the study (cross sectional). Study outcomes will be reported upon study completion, approximately 1 year from study onset.
Secondary outcomes:
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: University of Kansas Medical Center
state: Kansas
Study officials:
affiliation: Associate Professor
name: Dave Burnett, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02787096: Dynamic Knee Laxity Measurement Coupled to MRI in Cases of Suspected Partial Anterior Cruciate Ligament Tear
Official title: Dynamic Knee Laxity Measurement Coupled to MRI in Cases of Suspected Partial Anterior Cruciate Ligament Tear
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anterior Cruciate Ligament Tear
Keywords: dynamic knee laxity measurement
laxi-MRI
partial anterior cruciate ligament tear
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2016-06-01
Enrollment: 151
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Anterior cruciate ligament (ACL) tear is frequent, but the diagnosis of partial tears is difficult. Standard MRI may be used but is of limited diagnostic value. The present study aimed to evaluate the diagnostic interest of dynamic knee laxity measurement coupled to MRI for the diagnosis of ACL tear.


Eligibility criteria: Inclusion Criteria:

* knee injury requiring MRI examination
* accepting to participate
* covered by a health care insurance system

Exclusion Criteria:

* MRI contraindication
* pregnancy
* patient included in another study potentially affecting the results
* protected patients

Primary outcomes:
measure: Anterior tibial translation (ATT) measurement
timeFrame: 1 year after the baseline MRI-scan
Secondary outcomes:
measure: Degree of laxity
timeFrame: 1 year after the baseline MRI-scan
measure: Femorotibial rotation (FTR) value
timeFrame: 1 year after the baseline MRI-scan
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hospices Civils de Lyon - Hôpital Edouard Herriot Pavillon B Radiologie
Study officials:
affiliation: Hospices Civils de Lyon
name: Jean-Baptiste PIALAT, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03013296: Delinieation of GIP's Effects During a Meal in Humans Using GIP Receptor Antagonisation (GA-4)
Official title: Delinieation of GIP's Effects During a Meal in Humans Using GIP Receptor Antagonisation (GA-4)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glucose Metabolism Disorders
Keywords: GIP
GIP receptor antagonist
Lead sponsor: University Hospital, Gentofte, Copenhagen
Sponsor class: OTHER
Collaborators: name: University of Copenhagen
First posted: 2017-01-06
Enrollment: 12
Sex: MALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Delinieation of GIP's effects during a meal in humans using GIP receptor antagonisation.

Detailed description: Aim: To evaluate the role of GIPR signalling in postprandial physiology, including lipid, bone and glucose homeostasis, using a naturally occurring GIP fragment, which antagonises the GIPR.

Twelve healthy men (age 18-70 years, BMI 19-27 kg/m2) with normal kidney and liver parameters and haemoglobin levels and no first-degree relatives with type 2 diabetes will be included in a randomised, double-blinded, placebo-controlled cross-over study. Study consists of four study days with concomitant infusions of A) GIP-A, B) GLP-1 receptor antagonist Exendin\[9-39\], C) GIP-A + Exendin\[9-39\], or D) saline (placebo).

Eligibility criteria: Inclusion Criteria:

* Normal kidney function, liver function and hemoglobin levels.

Exclusion Criteria:

* Medication, Diabetes type 1 or 2, BMI \> 27, first degree relatives with Type 2 Diabetes

Primary outcomes:
measure: C-peptide levels
timeFrame: 180 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Center for Diabetes Research
state: Gentofte
Study officials:
affiliation: UHGentofte, Center for Diabetes Research
name: Fip K Knop, MD, PhD
role: STUDY_DIRECTOR
References:
citation: Helsted MM, Gasbjerg LS, Lanng AR, Bergmann NC, Stensen S, Hartmann B, Christensen MB, Holst JJ, Vilsboll T, Rosenkilde MM, Knop FK. The role of endogenous GIP and GLP-1 in postprandial bone homeostasis. Bone. 2020 Nov;140:115553. doi: 10.1016/j.bone.2020.115553. Epub 2020 Jul 27.
citation: Gasbjerg LS, Helsted MM, Hartmann B, Sparre-Ulrich AH, Veedfald S, Stensen S, Lanng AR, Bergmann NC, Christensen MB, Vilsboll T, Holst JJ, Rosenkilde MM, Knop FK. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgz175. doi: 10.1210/clinem/dgz175.
Clinical trial NCT01496716: Obesity's Impact on the Effect of Hip Arthroplasty
Official title: Obesity's Impact on the Clinical Efficacy and Quality of Life 1 Year After Primary Total Hip Arthroplasty
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hip Osteoarthritis
Keywords: Osteoarthritis
obesity
quality of life
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2011-12-21
Enrollment: 102
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All hip total hip replacement patients operated on Hospital Southern Jutland, Denmark.

Brief summary: The purpose of this study is to investigate whether there is a correlation between hip arthroplasty patients' preoperative weight and the patients quality of life and the clinical effect one year postoperatively.


Eligibility criteria: Inclusion Criteria:

* All patients recommended for primary total .

Exclusion Criteria:

* Rheumatoid arthritis.

Primary outcomes:
measure: SF-36
timeFrame: Measured 1 week before surgery and 12 months postoperatively
Secondary outcomes:
measure: HOOS
timeFrame: Measured 1 week before surgery and 12 months postoperatively
measure: Body composition
timeFrame: Measured 1 week before surgery and 12 months postoperatively
measure: Bone mineral density (BMD).
timeFrame: Measured 1 week before surgery and 12 months postoperatively
Other outcomes:
Locations:
city: Aarhus C
country: Denmark
facility: Department of Orthopedics Research Aarhus University Hospital
Study officials:
affiliation: Department of Orthopedics Research Aarhus University Hospital
name: Kjeld Søballe, professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06241716: Ultrasound-assisted Versus Real-time Ultrasound-guided Combined Spinal-epidural Anesthesia in Elderly Patients
Official title: Ultrasound-assisted Versus Real-time Ultrasound-guided Combined Spinal-epidural Anesthesia Via a Paramedian Approach in Elderly Patients: a Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Ultrasound Therapy; Complications
Lead sponsor: Tongji Hospital
Sponsor class: OTHER
First posted: 2024-02-05
Enrollment: 96
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This study aims to compare the clinical effects of ultrasound-assisted localization and real-time ultrasound-guided combined spinal-epidural anesthesia via paramedian approach in elderly patients

Detailed description: This study aims to compare the clinical effects of ultrasound-assisted localization and real-time ultrasound-guided combined spinal-epidural anesthesia via paramedian approach in elderly patients

Eligibility criteria: Inclusion Criteria:

* Elderly patients (≥ 60 years old);
* ASA Grade I to III.

Exclusion Criteria:

* Severe obesity (BMI\>35kg/m2);
* Spinal deformity or surgical history;
* Allergic to local anesthetics;
* There are coagulation disorders;
* Communication barriers

Primary outcomes:
measure: First puncture success rate
timeFrame: 1 year
Secondary outcomes:
measure: Procedure time
timeFrame: 1 year
measure: Positioning time
timeFrame: 1 year
measure: Depth and width of posterior dural complex
timeFrame: 1 year
measure: Skin puncture times
timeFrame: 1 year
measure: Number of redirects
timeFrame: 1 year
measure: Patient satisfaction score (How satisfied the patient is with the whole procedure)
timeFrame: 1 year
measure: Operator satisfaction score (How satisfied the patient is with the whole procedure)
timeFrame: 1 year
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Tianzhu Liu
state: Hubei
Study officials:
References:
Clinical trial NCT04376216: Prednisolone Treatment in Acute Interstitial Nephritis
Official title: Prednisolon Behandling Ved Akut Interstitiel Nefritis - et Randomiseret, Prospektivt Studie
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Acute Tubulo-Interstitial Nephritis
Keywords: Acute Tubulo-Interstitial Nephritis
Prednisone
Lead sponsor: Region MidtJylland Denmark
Sponsor class: OTHER
Collaborators: name: Aarhus University Hospital
name: Odense University Hospital
First posted: 2020-05-06
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Prospective randomized trial with a primary objective to investigate the effect ofprdenisolone treatment in acute interstitial nephritis


Eligibility criteria: Inclusion Criteria:

* Biopsy verified AIN
* Clinical suspicion of AIN
* Age \> 18 years
* One of following criteria:

  * Plasma creatinine \> 120 µmol/L or
  * Plasma creatinine increase \> 30 µmol/L or increase \> 50 % of baseline plasma creatinine
* Fertile women are included

Exclusion Criteria:

* No ability to give informed consent
* Immunosuppressive treatment (including prednisolone) within 3 months before biopsy
* Autoimmune disease
* Prednisolone intolerance
* Pregnancy or lactation
* Active cancer (except basal cell carcinoma)
* Short life expectancy (\< 6 months)
* CKD stage IV-V
* AIN secondary to or accompanied by glomerulonephritis, sarcoidosis or inherited interstitial renal disease
* Previous participation Withdrawal criteria
* Development of exclusion criterion
* Withdrawal of consent

Primary outcomes:
measure: eGFR
timeFrame: 3 months
Secondary outcomes:
measure: eGFR
timeFrame: 12 months
measure: Urinary biomarkers
timeFrame: at inclusion and after3 and 12 months
measure: Pathology
timeFrame: At inclusion
measure: Need for renal replacement therapy
timeFrame: 3 and 12 months
measure: Plasma glucose or hemoglobin A1C
timeFrame: 3 and 12 months
measure: Treatment delay
timeFrame: At inclusion
measure: Infections (number of events)
timeFrame: 3 and 12 months
measure: Admissions (number of events)
timeFrame: 3 and 12 months
Other outcomes:
Locations:
city: Herning
country: Denmark
facility: Godstrup Hospital
Study officials:
affiliation: Region MidtJylland Denmark
name: Jesper N Bech, MD
role: STUDY_CHAIR
References:
citation: Mose FH, Birn H, Hoffmann-Petersen N, Bech JN. Prednisolone treatment in acute interstitial nephritis (PRAISE) - protocol for the randomized controlled trial. BMC Nephrol. 2021 May 1;22(1):161. doi: 10.1186/s12882-021-02372-4.
Clinical trial NCT00893516: CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma
Official title: A Multicentre Open-label Dose Escalation Tiral of Zanolimumab in Combination With CHOP Chemotherapy in Patients With CD4 Positive Non-cutaneous Peripheral T-cell Lymphoma With Nodal Involvement.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: T-cell Lymphoma
Keywords: non cutaneous peripheral t-cell lymphoma with nodal involvement
Lead sponsor: Emergent BioSolutions
Sponsor class: INDUSTRY
First posted: 2009-05-06
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluation of CD4 in combination with CHO chemotherapy in subjects with nodal involvement of non cutaneous Tcell lymphoma.


Eligibility criteria: Inclusion Criteria:

* study is closed to enrollment

Exclusion Criteria:

* study is closed to enrollment

Primary outcomes:
measure: Primary Outcome Unavailable
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: